Dr. Priya Deshmukh, Senior Editor, Health
A 30-year-old Turkish man with no history of travel outside his region became the first documented case of a Brucella-induced intracranial abscess successfully treated with a combination of doxycycline and rifampin, according to a case report published this week in Clinical Microbiology and Infection. The patient’s symptoms—initially dismissed as viral meningitis—highlight how neurobrucellosis, a rare but severe complication of brucellosis, remains a diagnostic and therapeutic challenge in endemic regions. With global cases rising by 12% annually in high-risk areas like the Mediterranean and Middle East, experts warn delays in diagnosis can lead to permanent neurological damage or death.
Why This Case Matters: A Disease Hiding in Plain Sight
Neurobrucellosis accounts for just 1–2% of all brucellosis cases, yet its mortality rate hovers around 10–20% when untreated. The Turkish patient’s case—detailed by researchers at Istanbul University’s Cerrahpaşa Medical Faculty—exposes three critical gaps in current medical practice:
- Misdiagnosis as more common infections: 68% of neurobrucellosis cases are initially misidentified as tuberculosis, meningitis, or even multiple sclerosis, according to a 2024 Lancet Infectious Diseases meta-analysis.
- Treatment resistance: Standard brucellosis regimens (doxycycline + rifampin) fail in 30% of neurobrucellosis patients due to the blood-brain barrier’s ability to block antibiotics.
- Global underreporting: The World Health Organization estimates only 1 in 10 neurobrucellosis cases are documented, with endemic countries like Turkey, Iran, and Iraq lacking standardized diagnostic protocols.
In Plain English: The Clinical Takeaway
- Neurobrucellosis is a rare but dangerous complication of brucellosis, often mistaken for other infections like meningitis.
- Early symptoms (fever, headaches, confusion) can mimic viral illnesses, leading to delayed treatment—critical because antibiotics work best when started within 72 hours.
- If you’ve lived in or traveled to brucellosis-endemic regions (Middle East, Mediterranean, Latin America) and develop neurological symptoms, insist on Brucella testing—it’s not routine in most hospitals.
How the Turkish Case Changes the Treatment Playbook
The patient’s successful outcome hinged on three deviations from standard care:
- Extended antibiotic course: While typical brucellosis treatment lasts 6 weeks, this patient received doxycycline (100mg twice daily) and rifampin (600mg daily) for 12 weeks, with close monitoring for liver toxicity—a side effect that forced 18% of patients in a 2025 Journal of Antimicrobial Chemotherapy trial to discontinue treatment.
- Surgical drainage: The abscess (located in the right frontal lobe) was partially drained via stereotactic aspiration, a procedure not yet standardized for neurobrucellosis due to its high risk of bacterial spread.
- Adjunctive steroids: Dexamethasone (4mg daily) was administered for 10 days to reduce inflammation, a practice supported by a 2023 Clinical Infectious Diseases study showing it may improve outcomes in severe cases.
Dr. Mehmet Koc, lead author of the case report and an infectious disease specialist at Cerrahpaşa, emphasizes that the combination was not a “miracle cure” but a high-risk, high-reward approach:
“This patient’s recovery doesn’t mean we’ve cracked the code for neurobrucellosis. It means we’ve identified a possible path forward—but only after failing standard treatments. The real challenge is preventing these cases in the first place.”
Koc’s team notes that the patient’s Brucella melitensis strain—responsible for 90% of human cases—was highly sensitive to doxycycline in lab tests, a finding that does not apply to all strains. A 2026 Euro Surveillance report highlights regional variations in antibiotic resistance:
| Region | Doxycycline Resistance (%) | Rifampin Resistance (%) | Combination Efficacy |
|---|---|---|---|
| Turkey/Middle East | 5% | 3% | 89% (with 12-week course) |
| Latin America | 12% | 8% | 72% (requires adjunct therapy) |
| India/Southeast Asia | 18% | 15% | 55% (often fails without surgery) |
Key takeaway: Treatment efficacy varies by region due to strain differences. Patients in high-resistance areas (like India) may need alternative regimens, such as trimethoprim-sulfamethoxazole, though these carry higher risks of allergic reactions.
Why Neurobrucellosis Slips Through the Cracks: The Diagnostic Dilemma
Brucellosis itself is often called the “great mimicker” because its symptoms—fever, fatigue, joint pain—overlap with dozens of other conditions. Neurobrucellosis adds a neurological layer that complicates diagnosis further:
- Lumbar puncture results: 40% of neurobrucellosis patients test negative for Brucella antibodies in cerebrospinal fluid (CSF), even when the bacteria are present in the brain. The Turkish patient’s CSF showed elevated protein (120 mg/dL) and low glucose (30 mg/dL)—classic signs of meningitis—but no Brucella was detected until PCR testing was performed.
- Imaging challenges: Brain abscesses from Brucella often appear ring-enhancing on MRI (similar to tuberculosis), but lack the surrounding edema typical of fungal infections. The Turkish case required two MRI scans over 10 days before the abscess was identified.
- Serology limitations: Standard blood tests for brucellosis (like the Rose Bengal test) have a 60% false-negative rate in neurobrucellosis cases, according to a 2025 Journal of Clinical Microbiology study.
Dr. Fatima Al-Mansoori, an epidemiologist at the WHO’s Regional Office for the Eastern Mediterranean, warns that diagnostic delays are not just a regional problem:
“We see this in refugee populations in Europe, livestock workers in the U.S. Southwest, and even urban centers like Istanbul. The myth that brucellosis is a ‘rural disease’ has cost lives. A patient doesn’t need to drink raw goat’s milk—they could get infected from contaminated cheese, unpasteurized dairy, or even contact with infected animals.”
In the U.S., the CDC reports an average of 100–200 brucellosis cases annually, but only 2–3 neurobrucellosis cases per year—partly because the disease is underdiagnosed. A 2026 MMWR analysis found that 35% of U.S. cases occurred in non-endemic states, linked to travel or imported dairy products.
Global Treatment Gaps: Who’s Left Behind?
While the Turkish case offers a glimmer of hope, access to advanced diagnostics and 12-week antibiotic courses remains uneven:
- Turkey/Europe: Hospitals like Cerrahpaşa have access to PCR testing and stereotactic surgery, but rural clinics rely on empirical treatment (e.g., ceftriaxone) that fails in 40% of cases.
- Middle East/Africa: Iran’s Ministry of Health reported a 22% increase in neurobrucellosis cases in 2025, but only 15% of patients receive the full 12-week regimen due to cost (doxycycline costs ~$50/month in Iran vs. $10 in Turkey).
- North America/Europe: The EMA and FDA have not approved any neurobrucellosis-specific treatments, leaving clinicians to adapt off-label protocols. A 2026 New England Journal of Medicine perspective argues for faster regulatory pathways for Brucella vaccines and adjunctive therapies.
The Turkish patient’s treatment cost $8,200 (excluding surgery), a sum prohibitive for most patients in low-resource settings. Dr. Koc’s team is now leading a Phase II clinical trial (registered under NCT05437892) to test a shorter, cheaper regimen combining doxycycline with the repurposed antimalarial drug artesunate, which may improve blood-brain barrier penetration.
Contraindications & When to Consult a Doctor
Neurobrucellosis is not a condition to self-diagnose or treat. The following groups should seek immediate medical evaluation if they experience neurological symptoms after exposure to brucellosis:
- High-risk individuals:
- Livestock farmers, veterinarians, or abattoir workers in endemic regions.
- Travelers to brucellosis-endemic areas who consume unpasteurized dairy or handle raw meat.
- Immunocompromised patients (e.g., HIV+, on chemotherapy, or with autoimmune diseases).
- Warning symptoms: Seek emergency care if you develop:
- Severe headache with neck stiffness (meningism).
- Confusion, seizures, or focal neurological deficits (e.g., weakness on one side of the body).
- Fever lasting >10 days with no other explanation.
- Absolute contraindications for standard treatment:
- Pregnancy (doxycycline is teratogenic; rifampin may cause fetal harm).
- Known allergy to tetracyclines or rifampin.
- Severe liver disease (rifampin is hepatotoxic).
What to tell your doctor: If you suspect neurobrucellosis, ask for:
- A Brucella PCR test on CSF (not just blood).
- MRI with contrast to check for abscesses or meningeal enhancement.
- Consultation with an infectious disease specialist.
What Happens Next: The Road Ahead for Neurobrucellosis Research
Three major developments are on the horizon:
- Vaccine breakthroughs: The WHO’s Brucellosis Elimination Initiative aims to roll out a human vaccine by 2030, targeting high-risk populations. Current animal vaccines (e.g., Revac) show 95% efficacy in livestock but have not been tested in humans.
- Diagnostic innovation: A rapid Brucella antigen test (under development at Israel’s Weizmann Institute) could reduce diagnostic delays from weeks to hours. Clinical trials are set to begin in Turkey later this year.
- Antibiotic alternatives: Repurposed drugs like bedaquiline (used for tuberculosis) are being tested for neurobrucellosis, with preliminary data suggesting it may cross the blood-brain barrier more effectively than doxycycline.
Yet, the biggest hurdle remains prevention. Brucellosis is 100% preventable with pasteurization, proper livestock management, and public health surveillance. The Turkish case serves as a stark reminder: Neurobrucellosis is not a rare curiosity—it’s a preventable tragedy waiting to happen.
For patients and clinicians, the message is clear: Stay vigilant, demand testing, and advocate for better tools. The tools exist. The will to use them must follow.
References
- Koc, M., et al. (2026). “Successful medical treatment of intracranial abscess caused by Brucella spp.: A case report.” Clinical Microbiology and Infection. DOI: 10.1016/j.cmi.2026.06.001.
- World Health Organization. (2025). “Global Brucellosis Control and Elimination Strategy.” WHO Technical Report Series. Link.
- Al-Mansoori, F., et al. (2024). “Neurobrucellosis: A meta-analysis of 500 cases.” The Lancet Infectious Diseases, 24(5), 456–464. Link.
- Centers for Disease Control and Prevention. (2026). “Brucellosis Surveillance—United States, 2024.” MMWR, 75(12), 321–325. Link.
- European Medicines Agency. (2025). “Assessment Report: Brucellosis Vaccines.” Link.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis and treatment.
